Market Size of Global Diphenhydramine Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 2.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Diphenhydramine Market Analysis
The diphenhydramine market is expected to record a CAGR of around 2.0% over the forecast period (2022-2027).
COVID-19 has an impact on many facets of social life, medical procedures, and allergy diagnosis and management. One of the most crucial forms of treatment for IgE-mediated allergies is allergen-specific immunotherapy (AIT), which is based on the diseased person's immunological responses. As a result, the market is expanding because of the rising prevalence of allergies caused by the outbreak. The report published by the University of Florida Health in 2022 under the title 'Two common compounds show effectiveness against COVID-19 virus in early testing' stated that a combination of diphenhydramine and lactoferrin, a protein found in cow and human milk, the combination compounds were found to block the SARS-CoV-2 virus during tests in monkey cells and human lung cells. Moreover, as per the report published in March 2022 under the title 'Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection', histamine antagonists were linked to improved survival and slowed the onset of COVID-19 symptoms in critically ill individuals. These results are likely to cause the adoption of diphenhydramine during COVID-19. Thus, owing to the aforementioned factors COVID-19 had a significant impact on the diphenhydramine market.
An increased number of allergy cases and research and development initiatives in the fields of allergy are boosting the growth of the market. The 2020 update from the Centers for Disease Control and Prevention stated that depending on the allergen, allergic rhinitis symptoms may manifest only during seasons or all year round, affecting as many as 60 million Americans each year. As per the same source, pollen exposure can also trigger symptoms of allergic conjunctivitis. Allergic conjunctivitis is the inflammation of the lining of the eye (conjunctiva) due to exposure to allergens like those in pollen. Up to 30% of the general population and 7 out of 10 people with allergic rhinitis were likely to have allergic conjunctivitis in 2020.
Owing to the aforementioned factors diphenhydramine market is likely to grow over the forecast period. However, the side effect related to diphenhydramine restrains the market growth.
